摘要
目的探讨胸腺肽在小儿手足口病治疗中的临床应用价值。方法将84例手足口病患儿随机分成2组:实验组42例,对照组42例。对照组采用常规基础+利巴韦林静脉滴注治疗;实验组在对照组的基础上给予胸腺肽α1皮下/肌肉注射治疗。观察比较两组的临床疗效、住院时间和症状体征缓解时间、血液指标检测结果。结果实验组的总有效率高于对照组(P<0.05);实验组患儿平均住院时间、发热消退时间、手足皮疹消失时间、口腔疱疹消失时间、流涎改善时间、食欲恢复正常时间均明显短于对照组(P<0.05);实验组治疗后IgM、hs-CRP指标水平较对照组显著降低(P<0.05);实验组治疗后IgA、IgG指标水平较对照组显著升高(P<0.05)。结论临床应用胸腺肽α1注射液辅助治疗小儿手足口病效果显著。
Objective To investigate the clinical efficacy of thymosin cq treatment for children with hand- foot-and-mouth disease. Methods 84 hand-foot-and-mouth disease patients were randomly divided into two groups: control group( n = 42)and treatment group( n = 42 ). Control group was given conventional basic treatment and ribavirin, on the basis of the control group therapy, treatment group was treated with thymosin al. The clinical effects, average hospitalization days, remission time of symptoms and signs, and the results blood index test in the two groups was observed and compared. Results The total effective rate in treatment group was significantly higher than that in control group( P 〈 0. 05 ) ;the average hospitalization days, time of fever subsiding, foot and skin rash disappearing, oral herpes disappearing, salivation disappearing, and the appetite returning in the treatment group after treatment were significantly shorter than those in control group( P 〈 0. 05 ) ; the index value of hs-CRP, IgM in treatment group reduced more significantly than that in control group ( P 〈 0. 05 ) ; the index value of IgA, IgG in treatment group after treatment was significantly higher than that in control group ( P 〈 0. 05 ). Conclusion There is significant clinical efficacy of thymosin αl in treatment for children with hand-foot-and-mouth disease.
出处
《实用药物与临床》
CAS
2012年第9期555-556,共2页
Practical Pharmacy and Clinical Remedies
关键词
手足口病
胸腺肽Α1
Hand-foot-and-mouth disease
Thymosin αl